To homepage

Content meets the Bookimed Editorial Policy and is medically reviewed by

Fahad Mawlood

Mustafa Serkan Alemdar

  • 4.5 Good 6 reviews
  • 20 years of experience
  • Turkey, Antalya , Medical Park Antalya Hospital Complex
  • Education and Specialization

    • 2006: Kocaeli University Faculty of Medicine
    • 2014: Akdeniz University Faculty of Medicine, Internal Medicine
    • 2018: Akdeniz University Faculty of Medicine, Medical Oncology

    Experience

    • 2006 - 2008: Konya Derebucak District Hospital
    • 2009 - 2015: Akdeniz University Hospital
    • 2015: Antalya Kaş State Hospital
    • 2015 - 2016: İnönü University Faculty of Medicine
    • 2016 - 2021: Akdeniz University Hospital
    • 2021 - 2023: Antalya Training and Research Hospital
  • Read more
Hormone therapy
AUD $1,562 - AUD $1,562
Nephrectomy
AUD $11,356 - AUD $13,486
Info

Nail Paksoy

  • 4.5 Good 2 reviews
  • 15 years of experience
  • accreditation:
  • Turkey, Istanbul, Medipol Bahçelievler Univesity Hospital

  • PROFESSIONAL EXPERIENCE

    2011-2012
    Erzurum Koprukoyu State Hospital
    Department: General Medicine

    2012-2017
    Istanbul University Cerrahpaşa Medical Faculty
    Department: Internal Medicine

    06/2017-10/2017
    Istanbul Gaziosmanpasa Taksim Training and Research Hospital
    Department: Internal Medicine

    10/2017-11/2018
    Istanbul University Istanbul Medical Faculty
    Department: Allergy and Immunology Fellowship

    2018/2022
    Istanbul University Oncology Institute
    Department: Medical Oncology Fellowship

    2022-2023
    Tekirdag City Hospital
    Department: Medical Oncology Specialist

    2023-present
    Istanbul Medipol University Medipol Bahcelievler Private Hospital
    Department: Medical Oncology Assoc. Prof.

     

    EDUCATION

    2005-2011
    Medical Education
    Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

    2012-2017
    Internal Medicine
    Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

    2017-2018
    Allergy-Immunology Fellowship
    Istanbul University Istanbul Medical Faculty
    Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

    2018-2022
    Medical Oncology Fellowship
    Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

    2022
    ESMO Board Certification in Medical Oncology
    10th September 2022 in Paris, France.

    2023
    Medical Oncology Assoc. Prof.
    Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

     

    INTERNATIONAL CLINICAL TRIALS:

    1. Astefania - ROCHE

    • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
    • Role: Subinvestigator

    2. PFİZER

    • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
    • Role: Subinvestigator

    3. RECITE - AMGEN

    • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
    • Role: Subinvestigator

    4. NAVIGATE - BAYER

    • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    • Role: Subinvestigator

    5. RUBY - Tesaro (PRA)

    • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
    • Role: Subinvestigator

    6. ENGOT-ov43/GOG-3036 - MSD

    • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
    • Role: Subinvestigator

    7. ASTRA ZENECA

    • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
    • Role: Subinvestigator

    8. ROSY-O - ASTRA ZENECA

    • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
    • Role: Subinvestigator
    •  

    INTERNATIONAL PUBLICATIONS

    I. Published journal articles indexed by SCI, SSCI, and AHCI

    Weekly Paclitaxel in Classic Kaposi Sarcoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
    • Journal: Medicine, 102(5)

    Carboplatin Desensitization in Ovarian Carcinoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
    • Journal: Medicine, 101(45), e31726

    High-Dose Chemotherapy for Ewing’s Sarcoma

    • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
    • Journal: Medicine, 101(49), e32213

    Multidrug Refractory TFE3(+) Renal Cell Carcinoma

    • Authors: Paksoy, Nail, et al.
    • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

    Crizotinib Efficacy in NSCLC with MET Alterations

    • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
    • Journal: Medicine, 101(50), e32368

    Clinicopathological Features in ALK Mutant NSCLC

    • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
    • Journal: Medicine, 101(34)

    PSMA-Based Tumor Burden in Prostate Cancer

    • Authors: HAS SIMSEK, Duygu, et al.
    • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

    Atezolizumab in Metastatic Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: European Urology Focus, 2021, 7.5: 1061-1066

    Pulmonary Sarcomatoid Carcinoma

    • Authors: FERHATOGLU, Ferhat, et al.
    • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

    Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

    Atezolizumab with Chemotherapy in Small Cell Lung Cancer

    • Authors: GÜRBÜZ, Mustafa, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

    FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

    • Authors: AY, Seval, et al.
    • Journal: Journal of Chemotherapy, 2022, 1-7

    Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

    • Authors: CIL, Ibrahim, et al.
    • Journal: Tumori Journal, 2022, 108.1: 19-25

    Real-Life Efficacy of Osimertinib in Advanced NSCLC

    • Authors: HIZAL, Mutlu, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

    ALK-Positive Cells Percentage and Alectinib Efficacy

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
    • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

    Real-World Data on Alectinib in ALK-Positive NSCLC

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
    • Journal: Future Oncology, 18(23), 2573-2582

    Prognostic Factors in Metastatic RCC with T790M Mutation

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

    • Authors: DEMIR, Semra, et al.
    • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

    Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

    • Authors: ÖZDEMIR, Seçil Kepil, et al.
    • Journal: Allergy, 2019, 74.6: 1187-1190

    Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

    • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
    • Journal: The Oncologist, oyad257

    Subsequent Treatments in Hormone-Positive Breast Cancer Progression

    • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
    • Journal: BMC cancer, 23(1), 192

    Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
    • Journal: Scientific Reports, 13(1), 8779

    Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
    • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

    Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

    • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
    • Journal: European Journal of Breast Health, 19(2), 128

    Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

    • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
    • Journal: Future Oncology, 19(10), 727-736

    Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

    • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
    • Journal: [Not specified]

    Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

    • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
    • Journal: Medicine, 102(39), e35383

    Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

    • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
    • Journal: Medicine, 102(41), e35245

    Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

    Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

    Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

    Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

    Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

    Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

    Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

    Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

    Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

    Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

    Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

    Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

    Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

     

    Thesis:

    Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

    International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

    Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

    • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

    Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

    • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

    Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

    • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

    Efficacy of temozolomide in pretreated patients with metastatic sarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

    • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

    • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

    Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

    • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

    Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

    • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

    Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

    • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

     

     

  • Read more
Lung cancer surgery
AUD $21,293 - AUD $28,391
Removal of spinal cord tumor
AUD $17,035 - AUD $24,132
Radiotherapy for breast cancer
AUD $5,678 - AUD $8,517
Info

Gul Alco

  • 5 Excellent 3 reviews
  • 31 years of experience
  • Turkey, Istanbul, Medipol Acibadem District Hospital
  • Education

    • 1986-1989, Bursa High School, Bursa, Turkey
    • 1989-1995, Istanbul University, Istanbul School of Medicine, Turkey
    • 1999-2003, (Residency) Kadir Has University, School of Medicine, Department of Radiation Oncology, Istanbul, Turkey
    • 2015, (Associate Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
    • 2021, (Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
    • 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey

    Experience

    • 1995-1999, Şişli Florence Nightingale Hospital, Istanbul, Cardiology Department
    • 2003, Gayrettepe Florence Nightingale Hospital, Istanbul, Department of Radiation Oncology
    • 2015, (Associate Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
    • 2021, (Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
    • 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey
  • Read more
Doctor's visit
Price on request
Info

Esra Bahadir Ulger

  • 5 Excellent 3 reviews
  • 21 years of experience
  • Turkey, Istanbul, Medipol Acibadem District Hospital
Doctor's visit
Price on request
Info

Muhammed Mustafa Atci

  • 5 Excellent 1 review
  • 15 years of experience
  • Turkey, Istanbul, İstinye University Liv Hospital Topkapı
  • Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

    He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

    Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

  • Read more
Doctor's visit
Price on request
Info

Chayuth Fungthongjaroen

  • 17 years of experience
  • Thailand, Bangkok, He Clinic Bangkok
  • After graduating with a Medical Degree from Thammasat University, Dr. Chayut worked as an Intern in a Public Hospital for a year’s residency.

    For the next 6 years, he found his calling in Aesthetic Medicine Dr. Diacakis has performed enhancement procedures since 2001, and in fact, has been credited as one of the pioneers.

    Dr. Chayut and Dr. Diacakis met in 2014 at an Aesthetic Congress in Paris France. He has experience in many procedures such as rhinoplasty, anaplasty, mentoplasty, blepharoplasty, lip reduction, buccal fat removal, and enhancement.

  • Read more
Doctor's visit
Price on request
Info

Natthaphon Suwan

  • 14 years of experience
  • Thailand, Bangkok, Harmony Life Center
  • Dr. Natthaphon Suwan, M.D., M.Sc., ABAARM, focuses on Anti-Aging & Regenerative Medicine. He earned his M.D. from Chiang Mai University in 2012. He completed an M.Sc. in Anti-Aging & Regenerative Medicine at Dhurakij Pundit University in 2019. He also received a Master of Management in Health from Mahidol University in 2020. Languages: Thai and English.

    Board certifications: WOSAAM Board Diploma (2018); ABAARM/A4M (2019); Thai Board of Preventive Medicine, Public Health (2020). Professional memberships: WOSAAM, A4M, PMAT, CMAT, ACTTHAI, and TIMA.

    Current practice: BAAC (2019–present), Vejthani Q Life (2019–present), and UM The Exclusive Health Clinic (2020–present). Previous roles: Vibharam Hospital and World Medical Hospital. Clinical interests: IV therapies, ozone therapy, colon hydrotherapy, male hormones and TRT, PRP, stem cells, genetic cancer risk and NK cell therapy, food intolerance testing, and personalized supplementation. Additional training: A4M (2018–2019), CMAT (2019), ACTTHAI (2019), and H.E.A.T. (2020).

  • Read more
Doctor's visit
Price on request
Info

Sitthisak Jdhammawiwatnukul

  • 25 years of experience
  • Thailand, Bangkok, Harmony Life Center
  • Dr. Sitthisak Dhammawiatnukul, MD, ABAARM, specializes in Anti-Aging & Regenerative Medicine and Preventive Medicine. His focus areas include Cell Therapy, Aesthetic Medicine, Men’s Health, Gut Health, Hormone Management, and Detox. He practices at Harmony Life Center (2023–present). He also serves as Medical Advisor at Bio Sky Clinic (2010–present).

    Accreditations include the A4M Certificate in Anti-Aging and Regenerative Medicine (2011). He is an ISCT member with specialized certification in mesenchymal stem cells (MSCs). He attended the ISCT Annual Meeting in 2016. He completed the Thai Chelation Therapy Association Workshop, Level 17. He also holds certificates of attendance from A4M, the Thai Society of Cosmetic Dermatology and Surgery, the Thai Association of Cell Therapy, and the American Academy of Anti-Aging and Regenerative Medicine.

    Training includes non-surgical MSC therapy for knee rejuvenation. He has additional training in gut health, hormone management, and detox. He earned his MD from Chulalongkorn University and a BSc in Medical Technology from Mahidol University. He also holds a medical training certificate from 2003.

  • Read more
Doctor's visit
Price on request
Info

Mehmet Yigit

  • 4.9 Excellent 9 reviews
  • 36 years of experience
  • Turkey, Istanbul, Liv Hospital Vadistanbul
  • Dr. Mehmet Yigit is an internal medicine specialist. He focuses on diabetes, metabolic syndrome, thyroid diseases, and hypertension. He also treats gastrointestinal problems such as dyspepsia, gastritis, and irritable bowel syndrome. In addition, he manages spondylitis and connective tissue diseases.

    Dr. Yigit graduated from Çukurova University Faculty of Medicine in 2007. He completed his internal medicine training at Adnan Menderes University in 2013. He has worked as Assistant Chief Physician at Liv Hospital Ulus. He has held Medical Director roles at Recordati Rare Diseases and Alexion Pharmaceuticals. He has also held leadership positions at Abbvie and Novo Nordisk Pharmaceuticals. Dr. Yigit has served as an internal medicine physician at Manisa State Hospital. He has contributed to research as an assistant at ADU.

  • Read more
Chemotherapy
AUD $4,259 - AUD $4,968
Info

Turkan Ozturk Topcu

  • 16 years of experience
  • Turkey, Istanbul, Biruni University Hospital
  • Education

    Cumhuriyet University Faculty of Medicine, 2004
    Istanbul Haydarpaşa Training and Research Hospital Internal Medicine Residency, 2010
    Karadeniz Technical University Faculty of Medicine Medical Oncology Residency, 2015

    Experience

    MD Andeson Cancer Center, USA, 2008
    Sunnybrook Odette Cancer Center Breast Cancer Clinic, Canada, 2017
    Moffit Cancer Center , USA 2022
    Istanbul Haydarpaşa Training and Research Hospital Internal Medicine, 2010
    İdil State Hospital Internal Medicine Clinic, 2011
    Karadeniz Technical Universityniversitesi Faculty of Medicine, Medical Oncology Clinic, 2015
    Istanbul Göztepe Training and Research Hospital, Medical Oncology Clinic, 2018
    Yeniyüzyıl University Gaziosmanpaşa Hospital, Medical Oncology Clinic, 2020
    Ataşehir Medicana Hospital, Medical Oncology Clinic, 2022

     

    Scientific Membership

    Turkish Medical Association (TTB)
    Turkish Society of Medical Oncology (TTOD)
    European Society for Medical Oncology (ESMO)
    American Society of Medical Oncology (ASCO)

     

    Medical Intrests

    • Breast Cancer
    • Lung Cancer
    • Colon Cancer
    • Stomach Cancer
    • Rectal Cancer
    • Ovarian Cancer
    • Liver Cancer
    • Oesophageal Cancer - Oesophageal Cancer
    • Kidney Cancer
    • Larynx Cancer - Cancer of the Larynx
    • Thyroid Cancer
    • Head and Neck Cancers
    • Gynaecological Cancers
    • Pancreatic Cancer
    • Oesophageal Cancer - Oesophageal Cancer
    • Uterine Cancer
    • Brain Cancers - Brain Tumours
    • Soft Tissue Cancer - Sarcomas
    • Prostate Cancer
    • Bladder Cancer
    • Bile Tract Cancer
    • Testicular Cancer
    • Cervical Cancer
    • Mouth, Tongue, Lip Cancers
    • Gastrointestinal System Cancers
    • Bone Tumours
    • Trachea and Bronchial Cancers
    • Skin Cancers - Skin Cancers
    • Skeletal System Tumours
    • Gallbladder Cancer
    • Mesothelioma
  • Read more
Tomotherapy
AUD $11,981 - AUD $20,072
Brachytherapy
AUD $14,196 - AUD $17,035
Info

Senem Karabulut

  • 16 years of experience
  • Turkey, Istanbul, Biruni University Hospital
  • Education

    Istanbul University Cerrahpaşa Faculty of Medicine, 2002
    Istanbul Fatih Sultan Mehmet Training and Research Hospital, Internal Medicine, 2010
    Istanbul University Oncology Institute (Çapa), Medical Oncology, 2015
    Medipol University Faculty of Medicine, Phytotherapy Education, 2018
    University of Health Sciences, Vocational School of Health, Molecular Oncology, PhD Program, PhD, 2023

    Experience

    University Hospital, Newark, New Jersey, USA, Observer (2003-2004)
    Siirt State Hospital, Internal Medicine (2010-2011)
    Siirt State Hospital, Medical Oncology (2015)
    Bakırköy Dr. Sadi Konuk Training and Research Hospital, Medical Oncology (2015-2018)
    Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Medical Oncology, (Professor Doctor) (2018-Present)
    Forensic Medicine 3. Specialization Board, Medical Oncology, Full Member (2019-Present)
    Liv Hospital, Ulus, Park-time, Medical Oncology (2020-2022)
    Şişli Kolan International Hospital, Park-time, Medical Oncology (2022-2023)

     

    Medical Intrests

    • Gastrointestinal System Tumours (Esophagus - Stomach and Large Bowel Cancer)
    • Hepatobiliary System Tumours (Liver-Biliary Tract and Pancreatic Cancer)
    • Breast Cancer
    • Lung Cancer
    • Genitourinary Cancers
    • Immunotherapies and Target Therapies
    • Molecular Oncology
    • Immunotherapies
    • Target Treatments
    •  

    Awards

    2010-YDUS (Subspecialty Examination) 14th place in Turkey
    2014- Oncology Institute Days Best Poster Award
    2015- Turkish Medical Oncology Society Board Exam Qualification
    2015- ESMO (European Society for Medical Oncology) Board Exam Qualification

  • Read more
Tomotherapy
AUD $11,981 - AUD $20,072
Brachytherapy
AUD $14,196 - AUD $17,035
Info

Elnur Sahibov

  • 4.1 Good 42 reviews
  • 10 years of experience
  • Turkey, Istanbul, Emsey Hospital
  • The doctor completed specialization training in Radiation Oncology at Marmara University Faculty of Medicine from 2012 to 2016. Prior to this, the doctor completed an undergraduate degree in Medicine, taught in English, at the same institution from 2004 to 2011. The doctor has a strong foundation in medical education, beginning with high school education at Sixteen Numbered Shirvan School in Azerbaijan from 1998 to 2004.

  • Read more
Lobectomy
AUD $19,874 - AUD $36,908
Allogenic bone marrow transplantation from an unrelated donor
AUD $124,921 - AUD $124,921
Bone marrow transplantation
AUD $55,363 - AUD $140,536
Info

Tuba Efe

  • 4.5 Good 239 reviews
  • 36 years of experience
  • Turkey, Istanbul, Liv Hospital Ulus
  • Areas of Interests

    • Preventive Medicine
    • Functional Medicine
    • Healthy Living
    • Immunization
    • Check-Up
    • Tobacco Addiction and Smoking Cessation
    • Mesotherapy Applications
    • Phytotherapy

    Education:

    • Bursa İnegöl Mediha Hayri Çelik Science High School
    • Gazi University Faculty of Medicine
    • Specialization Training: Istanbul Haydarpaşa Numune Training and Research Hospital

     

    Experience:

    • Liv Hospital Ulus
    • Hatay Samandağ State Hospital
    • Istanbul Haydarpaşa Numune Training and Research Hospital
    • Bursa İnegöl District Health Directorate

     

    • Specialization Thesis: Evaluation of Healthy Eating Behaviors and Dietary Supplement Use Among Physicians - 2022
    • Oral Presentation at the 21st National Family Medicine Congress (TAHUD): Evaluation of Healthy Eating Behaviors and Dietary Supplement Use Among Physicians - 2022
    • Oral Presentation at the 8th İSTAHED Family Medicine Congress: How Did the Pandemic Affect Examinations and Follow-ups at a Training Family Health Center? - 2021
    •  
    • Turkish Association of Family Physicians Specialists (TAHUD)
    • Istanbul Medical Chamber
  • Read more
Immunotherapy
AUD $6,338 - AUD $6,338
Bone marrow transplantation
AUD $78,075 - AUD $127,760
Info

Alandag Celal

  • 5 Excellent 1 review
  • 17 years of experience
  • Turkey, Sivas, Medicana Sivas Hospital
Doctor's visit
Price on request
Info